CONTRACEPTION: THE CHOICE OPENS A WORLD OF POSSIBILITIES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To identify the factors influencing the prevalence of contraception, the additional requirements of women for its noncontraceptive benefits and their realization possibility in case of hyperandrogenic dermopathy. Materials and methods. The mixed method is a counseling procedure based on the ability to offer the wide range of contraceptive methods and devices, from which a user can choose one and further switch to another that best meets her needs during her sexual life. Results. The idea of the mixed method can be used in the combined oral contraceptives line (COCs) under the single umbrella brand Modelle. The additional needs of women suffering from hyperandrogenic dermopathy can be met when using an agent containing ethinyl estradiol (EE) 35 ßg and cyproterone acetate (CPA) 2 mg (35ЕЕ/ CPA- Modelle PURE), which can provide the maximum noncontraceptive (therapeutic) benefit. Conclusion. 35EE/CPA is the most suitable contraceptive for women with androgen-dependent skin diseases.

Full Text

Restricted Access

About the authors

Galina B. Dikke

Peoples' Friendship University of Russia

Email: galadikke@yandex.ru
honored worker of science and education, MD, Professor, Department of Obstetrics, Gynecology and Reproductive Medicine Faculty training of health workers Moscow 117198, Miklukho-Maklaya str. 8, Russia

References

  1. Method mix. USAID. MEASURE Evaluation Population and Reproductive Health (PRH). 2014. Available at: http://www.cpc.unc.edu/
  2. MacKenzie H., Drahota A., Pallikadavath S., Stones W., Dean T., Fogg C. et al. What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive prevalence, unmet need for family planning, and unwanted and unintended pregnancies? An overview of systematic reviews. EPPI-Centre, Social Science Research Unit, Institute of Education, University of London; 2013. 163p. Available at: http://r4d.dfid.gov.uk/
  3. Sullivan T.M., Bertrand J.T., Rice J., Shelton J.D. Skewed contraceptive method mix: why it happens, why it matters. J. Biosoc. Sci. 2006; 38(4): 501-21.
  4. Mestad R., Kenerson J., Peipert J. Reversible contraception update: the importance of long-acting reversible contraception. Postgrad. Med. 2009; 121(4): 18-25.
  5. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig. 2010;30:749-763.
  6. Volumetric concept test, Ipsos. Market research of COCs market potential. GFK; 2014. Available at: www.modelle.devup.cc
  7. Aydinlik S., Kaufmann J., Lachnit-Fixson U., Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination. Clin. Trials J. 1990; 27(6): 392-402.
  8. Kaunitz A.M., Portman D., Westhoff C.L., Archer D.F., Mishell D.R. Jr., Rubin A., Foegh M. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial. Obstet. Gynecol. 2014; 123(2, Pt 1): 295-303.
  9. Fan G.S., Bian M.L., Cheng L.N., Cao X.M., Huang Z.R., Han Z.Y. et al. Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi. 2009; 44(1): 38-44.
  10. Mansour D., Verhoeven C., Sommer W., Weisberg E., Taneepanichskul S., Melis G.B. et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17ß-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept. Reprod. Health Care. 2011; 16(6): 430-43.
  11. Endrikat J., Parke S., Trummer D., Schmidt W., Duijkers I., Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008; 78(3): 218-25.
  12. Falsetti L., Dordoni D., Gastaldi C., Gastaldi A. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome. Acta Eur. Fertil. 1986; 17(1): 19-25.
  13. Gollnick H., Albring M., Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann. Endocrinol. (Paris). 1999; 60(3): 157-66.
  14. Соболева Е.Л., Потин В.В., Тарасова М.А. Лечение андрогензависимой дермопатии. Журнал акушерства и женских болезней. 2010; 59(3): 60-7.
  15. Burkman R.T., Fisher A.C., LaGuardia K.D. Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use. J. Reprod. Med. 2007; 52(11): 1030-4.
  16. Gallo M.F., Lopez L.M., Grimes D.A., Carayon F., Schulz K.F., Helmerhorst F.M. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev. 2014; (1): CD003987. doi: 10.1002/14651858.CD003987.pub5. Available at: http://www.ncbi.nlm.nih.gov/
  17. Åkgren U.M., Anttila M., Mäenpää-Liukko K., Rantala M.L., Rautiainen H., Sommer W.F., Mommers E. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17ß-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur. J. Contracept. Reprod. Health Care. 2011; 16: 444-57.
  18. Ahrendt H.J., Makalovd D., Parke S., Mellinger U., MansourD. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436-44.
  19. Прилепская В.Н., Назарова Н.М., Тарасова М.А., Летуновская А.Б. Международный проект «CHOICE»: краткий обзор результатов исследования. Гинекология. 2010; 12(4): 26-8
  20. Kost K., Singh S., Vaughan B., Trussell J., Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008; 77(1): 10-21.
  21. Sitruk-Ware R., Nath A., Mishell D.R. Contraception technology: past, present and future. Contraception. 2013; 87(3): 319-30.
  22. Монахов С.А., Иванов О.Л., Самгин М.А. Антиандрогенные препараты: современная терапия акне у женщин. Гинекология. 2005; 7(5-6): 276-82.
  23. Хамошина М.Б., Шестакова И.Г., Дикке Г.Б., Кайгородова Л.А. Синдром гиперандрогении у молодых женщин: клинические возможности комбинированных оральных контрацептивов. Доктор.Ру. 2015; 1: 9-16
  24. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for the treatment of acne. Cochrane Database Syst. Rev. 2012; (7): CD004425. doi: 10.1002/14651858.CD004425.pub6. Available at: http://www. ncbi.nlm.nih.gov/
  25. Pasquali R., Gambineri A. Treatment of hirsutism in the polycystic ovary syndrome. Eur. J. Endocrinol. 2013; 170(2): 75-90.
  26. Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin. Drug Investig. 2009; 29(2): 73-8.
  27. Schindler A. E. Non-contraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. Metab. 2013; 11(1): 41-7.
  28. Huber J., Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception. 2006; 73(1): 23-9.
  29. van Wayjen R.G., van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp. Clin. Endocrinol. Diabetes. 1995; 103(4): 241-51.
  30. Fugère P., Percival-Smith R.K., Lussier-Cacan S., Davignon J., Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception. 1990; 42(2): 225-34.
  31. Falsetti L., Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1990; 42(6): 611-9.
  32. Franks S., Layton A., Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum. Reprod. 2008; 23(2): 231-2.
  33. Cao H., Yang G., Wang Y., Liu J., Smith C.A., Luo H., Liu Y. Complementary therapies for acne vulgaris. Cochrane Database Syst. Rev. 2015; (1): CD009436. doi: 10.1002/14651858.CD009436.pub2. Available at: http://www.ncbi.nlm.nih.gov/
  34. van der Spuy Z.M., Le Roux P.A., Matjila M.J. Cyproterone acetate appears to be as effective as other medications for hirsutism in women caused by excessive androgen production by the ovaries. Cochrane Database Syst. Rev. 2003; (4): CD001125. Available at: http://www.ncbi.nlm.nih.gov/
  35. Badawy A., Elnashar A. Treatment options for polycystic ovary syndrome. Int. J. Womens Health. 2011; 3: 25-35.
  36. Sahin Y., Bayram F., Keleştimur F., Müderris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J. Endocrinol. Invest. 1998; 21(6): 348-52.
  37. Lobo R.A., Shoupe D., Serafini P., Brinton D., Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Ferti.l Steril. 1985; 43(2): 200-5.
  38. Spritzer P.M., Lisboa K.O., Mattiello S., Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin. Endocrinol. (Oxford). 2000; 52(5): 587-94.
  39. Moran L.J., Hutchison S.K., Norman R.J., Teede H.J. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. 2011; (7): CD007506. doi: 10.1002/14651858.CD007506.pub3. Available at: http://www. ncbi.nlm.nih.gov/
  40. van Zuuren E.J., Fedorowicz Z., Carter B., Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst. Rev. 2015; (4): CD010334. doi: 10.1002/14651858.CD010334.pub2. Available at: http://www.ncbi.nlm.nih.gov/
  41. Schindler A.E., Mangold K., Friedrich E., Keller E., Göser R. Therapy of androgenetic sympatomatology with cyproterone acetate and ethinyl estradiol. Arch. Gynakol. 1978; 225(2): 103-7.
  42. Moltz L., Kaiser E. Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study. Geburtshilfe Frauenheilkd. 1984; 44(1): 47-52.
  43. Sinclair R., Wewerinke M., Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br. J. Dermatol. 2005; 152(3): 466-73.
  44. Levy L.L., Emer J.J. Female pattern alopecia: current perspectives. Int. J. Womens Health. 2013; 5: 541-56.
  45. Алейникова А.Л. Оценка метаболизма стероидных гормонов и эффективности антиандрогенных препаратов в лечении андрогенной алопеции у женщин репродуктивного возраста: автореф. дисс.. канд. мед. наук. М.; 2005. 24с
  46. Brzezinska-Wcislo L. Assessment of efficacy of Diane-35 in androgenetic feminine alopecia. Wiad. Lek. 2003; 56(3-4): 202-5.
  47. Lucky A.W., Piacquadio D.J., Ditre C.M., Dunlap F., Kantor I., Pandya A.G. et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J. Am. Acad. Dermatol. 2004; 50(4): 541-53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies